Larry Biegelsen
Stock Analyst at Wells Fargo
(4.03)
# 449
Out of 4,791 analysts
306
Total ratings
54.87%
Success rate
8.21%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Equal-Weight | $35 → $22 | $14.68 | +49.86% | 11 | Apr 3, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $28 | $24.43 | +14.64% | 1 | Mar 31, 2025 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $24 → $15 | $13.62 | +10.17% | 5 | Mar 28, 2025 | |
| HYPR Hyperfine | Maintains: Equal-Weight | $1.1 → $1.29 | $0.69 | +87.58% | 4 | Mar 18, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $38 → $22 | $18.09 | +21.61% | 8 | Mar 3, 2025 | |
| TFX Teleflex | Maintains: Equal-Weight | $214 → $146 | $141.00 | +3.55% | 4 | Feb 28, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $120 → $117 | $105.08 | +11.35% | 8 | Feb 26, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $153 → $160 | $92.16 | +73.61% | 13 | Feb 21, 2025 | |
| PEN Penumbra | Maintains: Overweight | $275 → $305 | $273.10 | +11.68% | 17 | Feb 19, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $96 → $103 | $71.64 | +43.78% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $198 → $195 | $155.15 | +25.68% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $118 | $98.57 | +19.71% | 13 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $12.41 | +36.99% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $427 → $435 | $367.61 | +18.33% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $630 → $687 | $492.69 | +39.44% | 19 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $166 → $152 | $158.06 | -3.83% | 13 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $6.65 | +20.30% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $94 | $62.82 | +49.63% | 9 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $78.93 | +49.50% | 16 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $98 | $88.02 | +11.34% | 17 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $117 | $112.47 | +4.03% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $80 | $71.68 | +11.61% | 15 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $105 | $92.05 | +14.07% | 8 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $44 → $40 | $31.80 | +25.79% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $40 | $16.94 | +136.13% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $14 | $5.84 | +139.73% | 11 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $20.73 | +136.43% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $131.89 | +3.12% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $73.16 | -4.32% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $221.89 | +21.68% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $94.90 | - | 2 | Nov 2, 2017 |
RxSight
Apr 3, 2025
Maintains: Equal-Weight
Price Target: $35 → $22
Current: $14.68
Upside: +49.86%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $28
Current: $24.43
Upside: +14.64%
Bausch + Lomb
Mar 28, 2025
Downgrades: Equal-Weight
Price Target: $24 → $15
Current: $13.62
Upside: +10.17%
Hyperfine
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $1.1 → $1.29
Current: $0.69
Upside: +87.58%
Tandem Diabetes Care
Mar 3, 2025
Downgrades: Equal-Weight
Price Target: $38 → $22
Current: $18.09
Upside: +21.61%
Teleflex
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $214 → $146
Current: $141.00
Upside: +3.55%
Merit Medical Systems
Feb 26, 2025
Maintains: Overweight
Price Target: $120 → $117
Current: $105.08
Upside: +11.35%
Glaukos
Feb 21, 2025
Maintains: Overweight
Price Target: $153 → $160
Current: $92.16
Upside: +73.61%
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $275 → $305
Current: $273.10
Upside: +11.68%
GE HealthCare Technologies
Feb 14, 2025
Maintains: Overweight
Price Target: $96 → $103
Current: $71.64
Upside: +43.78%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $198 → $195
Current: $155.15
Upside: +25.68%
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $118
Current: $98.57
Upside: +19.71%
Jan 30, 2025
Maintains: Overweight
Price Target: $13 → $17
Current: $12.41
Upside: +36.99%
Jan 29, 2025
Maintains: Overweight
Price Target: $427 → $435
Current: $367.61
Upside: +18.33%
Jan 24, 2025
Maintains: Overweight
Price Target: $630 → $687
Current: $492.69
Upside: +39.44%
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $166 → $152
Current: $158.06
Upside: -3.83%
Dec 11, 2024
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $6.65
Upside: +20.30%
Dec 11, 2024
Maintains: Overweight
Price Target: $90 → $94
Current: $62.82
Upside: +49.63%
Dec 6, 2024
Maintains: Overweight
Price Target: $115 → $118
Current: $78.93
Upside: +49.50%
Nov 20, 2024
Maintains: Overweight
Price Target: $106 → $98
Current: $88.02
Upside: +11.34%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $110 → $117
Current: $112.47
Upside: +4.03%
Sep 9, 2024
Maintains: Overweight
Price Target: $90 → $80
Current: $71.68
Upside: +11.61%
Aug 22, 2024
Maintains: Overweight
Price Target: $94 → $105
Current: $92.05
Upside: +14.07%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $44 → $40
Current: $31.80
Upside: +25.79%
Jul 26, 2024
Maintains: Overweight
Price Target: $42 → $40
Current: $16.94
Upside: +136.13%
Apr 8, 2024
Maintains: Equal-Weight
Price Target: $17 → $14
Current: $5.84
Upside: +139.73%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $20.73
Upside: +136.43%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $131.89
Upside: +3.12%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $73.16
Upside: -4.32%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $221.89
Upside: +21.68%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $94.90
Upside: -